BOLT News and Press, Bolt Biotherapeutics Inc. From 04/06/22

Shares of Bolt Biotherapeutics Inc. (NASDAQ:BOLT) traded today at $42.41, eclipsing its 52-week high. Approximately 4.3 million shares have changed hands today, as compared to an average 30-day volume of 184,000 shares. Bolt Biotherapeutics Inc. (NASDAQ:BOLT) is currently priced 7.9% abo...

Bolt Therapeutics (NASDAQ:BOLT) has filed for a $250M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for working capital and general corporate purposes. The offering can include co...

Bolt Biotherapeutics press release (NASDAQ:BOLT): Q4 GAAP EPS of -$0.73 misses by $0.04. Revenue of $0.51M. Cash, cash equivalents, and marketable securities were $271.6 million as of December 31, 2021, which is expected to fund operations and the advancement of the Company's oncology product...

BDC-1001 for the treatment of patients with HER2-expressing solid tumors on track for recommended Phase 2 dose identification later in 2022; BDC-1001 combination study arm with OPDIVO® (nivolumab) progressing well Preclinical data on multiple pipeline programs will be prese...

REDWOOD CITY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine the targeting precision of antibodies with the power of both the innate and adaptive immun...

REDWOOD CITY, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune syste...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Usually, investment writers bury the fine print at the end of the article. You know the story, though: all investments involve risk and therefore, you must practice due diligence. That’s fine when discussing blue-chi...

REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune...

Last week was an especially rough one for several small biotechs. Disappointing news for Aeglea BioTherapeutics (NASDAQ: AGLE) , Bolt Biotherapeutics (NASDAQ: BOLT) , and Reata Pharmaceuticals (NASDAQ: RETA) caused shares of all three companies to plunge. In this ...

REDWOOD CITY, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune syste...